Agios Pharmaceuticals Ownership | Who Owns Agios Pharmaceuticals?
Agios Pharmaceuticals Ownership Summary
Agios Pharmaceuticals is owned by 113.15% institutional investors, 1.07% insiders. Blackrock funding, inc. /de is the largest institutional shareholder, holding 10.47% of AGIO shares. BB Biotech AG Ord is the top mutual fund, with 6.34% of its assets in Agios Pharmaceuticals shares.
AGIO Ownership Benchmark
| Type | Name | % Inst | % Insiders | % Retail |
|---|---|---|---|---|
| Stock | Agios Pharmaceuticals | 113.15% | 1.07% | -14.22% |
| Sector | Healthcare Stocks | 129.40% | 12.08% | -41.48% |
| Industry | Biotech Stocks | 181.71% | 11.69% | -93.40% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
| Holder | Shares | % Holding | Value |
|---|---|---|---|
| Blackrock funding, inc. /de | 6.23M | 10.47% | $207.12M |
| Farallon capital management | 5.92M | 10.07% | $219.59M |
| Vanguard group | 5.59M | 9.62% | $152.28M |
| Blackrock | 4.86M | 8.55% | $209.52M |
| Bellevue group | 3.71M | 6.41% | $149.11M |
| Lynx1 capital management lp | 3.41M | 5.80% | $126.51M |
| Morgan stanley | 3.44M | 5.78% | $114.27M |
| State street | 3.26M | 5.49% | $108.55M |
| D. e. shaw | 3.11M | 5.29% | $115.30M |
| Vanguard portfolio management | 2.85M | 4.79% | $94.77M |
Top Institutional Shareholders by % of Total Assets
| Holder | Shares | % Assets | Value |
|---|---|---|---|
| Lynx1 capital management lp | 3.41M | 24.92% | $126.51M |
| Caligan partners lp | 1.13M | 5.95% | $45.41M |
| Commodore capital lp | 2.34M | 4.58% | $93.86M |
| Foresite capital management vi | 785.00K | 4.53% | $29.13M |
| Cutter capital management, lp | 301.62K | 4.06% | $9.91M |
| Bellevue group | 3.71M | 3.10% | $149.11M |
| Paradigm biocapital advisors lp | 2.67M | 3.05% | $107.32M |
| Parkman healthcare partners | 669.05K | 2.54% | $24.83M |
| Adar1 capital management | 1.29M | 2.19% | $47.80M |
| Exome asset management | 70.50K | 1.61% | $2.62M |
Top Buyers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Morgan stanley | 3.44M | 0.01% | 2.47M |
| Assenagon asset management | 1.89M | 0.06% | 1.78M |
| Paradigm biocapital advisors lp | 2.67M | 3.05% | 1.53M |
| Adar1 capital management | 1.29M | 2.19% | 1.15M |
| Lynx1 capital management lp | 3.41M | 24.92% | 797.37K |
Top Sellers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Macquarie group | - | - | -1.96M |
| T. rowe price investment management | - | - | -1.49M |
| Bioimpact capital | - | - | -1.31M |
| Frazier life sciences management | - | - | -1.26M |
| Tcg crossover management | - | - | -1.18M |
New Positions
| Holder | Shares | % Assets | Change | Value |
|---|---|---|---|---|
| Renaissance | 505.60K | 0.02% | 505.60K | $16.81M |
| Axa investment managers | 177.68K | 0.02% | 177.68K | $7.13M |
| Norges bank | 145.09K | 0.00% | 145.09K | $4.77M |
| Jain global | 91.65K | 0.01% | 91.65K | $3.40M |
| Walleye capital | 56.60K | 0.00% | 56.60K | $1.88M |
Sold Out
| Holder | Change |
|---|---|
| Hughes financial services | -1.00 |
| National bank of canada /fi/ | -1.00 |
| Dinuzzo private wealth | -1.00 |
| Riggs asset managment | -3.00 |
| Global financial private client | -3.00 |
Institutional Ownership Trends
| Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | 255 | 1.19% | 67,312,933 | 1.16% | 113 | 0.88% | 136 | 0.74% | 64 | -3.03% |
| Jun 30, 2026 | 249 | 0.40% | 66,448,353 | 5.41% | 113 | 0.98% | 134 | 9.84% | 64 | -16.88% |
| Mar 31, 2026 | 246 | -3.91% | 63,038,205 | 2.90% | 108 | 0.98% | 123 | -13.99% | 76 | 7.04% |
| Dec 31, 2025 | 165 | -31.82% | 34,473,117 | -45.71% | 59 | 0.49% | 89 | -24.58% | 49 | -28.99% |
| Sep 30, 2025 | 229 | 9.05% | 60,859,306 | 3.40% | 105 | 1.02% | 111 | 4.72% | 67 | -6.94% |
Top Mutual Funds Shareholders
| Holder | Shares | % Holding | Change |
|---|---|---|---|
| BB Biotech AG Ord | 3.71M | 6.34% | 124.59K |
| Vanguard MStar Total Stk Mkt Idx Invest | 1.90M | 3.19% | 8.33K |
| Vanguard Morn Total Stk Mkt Idx Investor | 1.89M | 3.18% | 718.00 |
| Vanguard Total Stock Mkt Idx Inv | 1.89M | 3.18% | 718.00 |
| Vanguard US Total Market Shares ETF | 1.79M | 3.12% | 2.35K |
| State Street® SPDR® S&P® Biotech ETF | 1.83M | 3.06% | 47.81K |
| Nomura US Small Cap Core Equity | 1.70M | 2.85% | 513.26K |
| Nomura Small Cap Core I | 1.70M | 2.83% | - |
| iShares Russell 2000 ETF | 1.50M | 2.51% | - |
| Macquarie Small Cap Core I | 1.43M | 2.46% | -107.41K |
Recent Insider Transactions
| Date | Name | Role | Activity | Value |
|---|---|---|---|---|
| Oct 26, 2026 | Gheuens Sarah | Chief Medical Officer | Sell | $296.47K |
| Oct 21, 2026 | Gheuens Sarah | Chief Medical Officer | Sell | $55.88K |
| Oct 22, 2026 | Gheuens Sarah | Chief Medical Officer | Sell | $18.76K |
| Aug 04, 2026 | Gheuens Sarah | Chief Medical Officer | Sell | $914.40K |
| Jul 01, 2026 | Gheuens Sarah | Chief Medical Officer | Sell | $150.50K |
Insider Transactions Trends
| Date | Buy | Sell |
|---|---|---|
| 2026 Q4 | - | 3 |
| 2026 Q3 | - | 2 |
| 2026 Q2 | - | 7 |
| 2026 Q1 | - | 22 |
| 2025 Q4 | - | 11 |
AGIO Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools